Loading...
Loading...
Takeda Pharmaceutical Company Limited
TKPYY today announced interim
data from a Phase 1/2, open-label, multicenter study with ADCETRIS®
(brentuximab vedotin) in pediatric patients diagnosed with CD30-positive
relapsed or refractory Hodgkin lymphoma (HL) or relapsed or refractory
systemic anaplastic large cell lymphoma (sALCL). Data were presented
from the Phase 1 portion of the study, which evaluated the safety,
maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and
pharmacokinetics (PK) of ADCETRIS. The results were reported during a
poster presentation at the American Society of Clinical Oncology (ASCO)
Annual Meeting held May 31 – June 4, 2013 in Chicago, IL.
ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a
defining marker of
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in